Recipharm Bolsters pharma development capabilities with strategic funding

Recipharm, a top global pharmaceutical CDMO, is enhancing its pharmaceutical development abilities by making strategic investments and incorporating advanced technologies. This investment enhances its offerings for both early and late-stage product development, such as supplying clinical study materials on a small and pilot scale and various commercial technologies.

After making this investment, Recipharm will offer services that cover every stage of a molecule's life cycle, from scouting APIs to manufacturing pharmaceutical products for commercial purposes.

Recipharm's development facilities, strategically placed in Europe, the US, and India, are furnished with cutting-edge technology and infrastructure to provide science-driven solutions. Following the Quality by Design (QbD) principle, Recipharm's specialists utilize the advanced ReciPredict platform, blending material- and process- sciences, statistical tools, modelling and simulation to enhance the creation of stable products.

Recipharm's Bengaluru, India centre of excellence for small molecules (NCEs and generics) is enhancing its capabilities by adding a new laboratory for sterile product development. This adds to the new Extractables and Leachables, Nitrosamines and Elemental Impurities labs, making them Recipharm's main site for thorough analytical services.

The pharmaceutical company has enhanced its abilities in pre-clinical, clinical, and pilot scale sterile development for small and large molecules, such as liquid vials, pre-filled syringes, blow-fill-seal, and lyophilized products.